148 related articles for article (PubMed ID: 19436299)
21. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).
Molthoff CF; Klabbers BM; Berkhof J; Felten JT; van Gelder M; Windhorst AD; Slotman BJ; Lammertsma AA
Mol Imaging Biol; 2007; 9(6):340-7. PubMed ID: 17643202
[TBL] [Abstract][Full Text] [Related]
22. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
[TBL] [Abstract][Full Text] [Related]
23. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.
Weidensteiner C; Allegrini PR; Sticker-Jantscheff M; Romanet V; Ferretti S; McSheehy PM
BMC Cancer; 2014 Feb; 14():88. PubMed ID: 24528602
[TBL] [Abstract][Full Text] [Related]
24. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.
Bruechner K; Bergmann R; Santiago A; Mosch B; Yaromina A; Hessel F; Hofheinz F; van den Hoff J; Baumann M; Beuthien-Baumann B
Int J Radiat Biol; 2009 Sep; 85(9):772-80. PubMed ID: 19657862
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
26. Early Changes in [
Dockx Y; Vangestel C; Van den Wyngaert T; Huizing M; De Bruycker S; Pauwels P; Staelens S; Stroobants S
Mol Imaging; 2021; 2021():5594514. PubMed ID: 34113218
[TBL] [Abstract][Full Text] [Related]
27. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD; Kim S; Saba NF; Pickens A; Behera M; Fu RW; Rossi MR; Auffermann WF; Torres WE; Bechara R; Deng X; Sun SY; Fu H; Gal AA; Khuri FR
Clin Cancer Res; 2015 Apr; 21(8):1859-68. PubMed ID: 25673697
[TBL] [Abstract][Full Text] [Related]
28. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
Yang L; Clarke MJ; Carlson BL; Mladek AC; Schroeder MA; Decker P; Wu W; Kitange GJ; Grogan PT; Goble JM; Uhm J; Galanis E; Giannini C; Lane HA; James CD; Sarkaria JN
Clin Cancer Res; 2008 Jun; 14(12):3993-4001. PubMed ID: 18559622
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
30. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
31. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
32. RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia.
Erdemoglu E; Güney M; Take G; Giray SG; Mungan T
Int J Gynecol Cancer; 2009 Apr; 19(3):375-9. PubMed ID: 19407562
[TBL] [Abstract][Full Text] [Related]
33. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
34. Clinical development of mammalian target of rapamycin inhibitors.
Dancey JE
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1101-14. PubMed ID: 12512385
[TBL] [Abstract][Full Text] [Related]
35.
Jiang Y; Zeng Q; Jiang Q; Peng X; Gao J; Wan H; Wang L; Gao Y; Zhou X; Lin D; Feng H; Liang S; Zhou H; Ding J; Ai J; Huang R
Theranostics; 2022; 12(14):6395-6408. PubMed ID: 36168616
[No Abstract] [Full Text] [Related]
36. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
37. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
38. Deciphering PDT-induced inflammatory responses using real-time FDG-PET in a mouse tumour model.
Cauchon N; Hasséssian HM; Turcotte E; Lecomte R; van Lier JE
Photochem Photobiol Sci; 2014 Oct; 13(10):1434-43. PubMed ID: 25058054
[TBL] [Abstract][Full Text] [Related]
39. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Courtney KD; Manola JB; Elfiky AA; Ross R; Oh WK; Yap JT; Van den Abbeele AD; Ryan CW; Beer TM; Loda M; Priolo C; Kantoff P; Taplin ME
Clin Genitourin Cancer; 2015 Apr; 13(2):113-23. PubMed ID: 25450031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]